Journal of Clinical Immunology

, Volume 8, Issue 4, pp 244–249 | Cite as

Delay and not deficiency in cap formation of peripheral blood B cells in patients with multiple myeloma

  • Xue-Guang Zhang
  • Bernard Klein
  • Christophe Duperray
  • Jean Brochier
  • Regis Bataille
Original Articles


A major problem in the study of peripheral blood (PB) B cells from patients with multiple myeloma (MM) is the distinction between the cells really able to synthesize membrane (m) immunoglobulins (Ig) and those able only to absorb serum Ig passively, since the lymphocytes of such patients are bathed in very high concentrations of monoclonal Ig. In order to reappraise PB B cells (including putative pre-B cells) in MM, we have used three different criteria: (a) the capacity of PB B cells to cap mIg when triggered by an anti-Ig; (b) the presence of B-cell differentiation antigens (CD19, CD20, CD21, and CD37) as specific B-cell markers; and (c) the expression of cytoplasmic μ heavy chain as a marker of pre-B cells. We have found that, in active myeloma (N=13), the percentages and absolute numbers of PB B cells able to cap mIg (4.25%; 45.43 cells/mm3) were significantly lower than those in healthy donors (8.4%; 151.2 cells/mm3) and those in stable MM (7.67%; 134.39 cells/mm3). In addition, the capping formation in patients with stable or active MM was significantly delayed compared to that in healthy donors. For all the normal individuals and patients investigated, there has been found an excellent correlation between the percentages and absolute numbers of PB B cells able to cap their mIg and those of PB mononuclear cells bearing the four B cell-specific differentiation antigens: CD19, CD20, CD21, and CD37. Finally, virtually no pre-B cells bearing cytoplasmic μ chains have been identified in the peripheral blood from healthy donors and patients with MM.

Key words

B cells capping multiple myeloma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mellstedt H, Holm G, Björkholm M: Multiple myeloma, Waldenström's macroglobulinemia and benign monoclonal gammapathy: Characteristics of the B cell clone, immunoregulatory cell population and clinical implications. Adv Cancer Res 41:257–289, 1984Google Scholar
  2. 2.
    Lindström FD, Hardy WR, Eberle BJ, William RC: Multiple myeloma and benign monoclonal gammopathy: Differentiation by immunofluorescence of lymphocytes. Ann Intern Med 78:837–844, 1973Google Scholar
  3. 3.
    Seligmann M, Preud'Homme JL, Brouet JC: B and T cell markers in human proliferative blood diseases and primary immunodeficiencies, with special reference to membrane bound immunoglobulin. Transplant Rev 16:85–113, 1973Google Scholar
  4. 4.
    Knapp W, Schuit HRE, Bolhuis RLH, Hijmans W: Surface immunoglobulins in chronic lymphocytic leukemia, macroglobulinemia and myelomatosis. Clin Exp Immunol 16:541–552, 1974Google Scholar
  5. 5.
    Mellstedt H, Hammarström JL, Holm G: Monoclonal lymphocytes population in human plasma cell myeloma. Clin Exp Immunol 17:371–384, 1974Google Scholar
  6. 6.
    Abdou NI, Abdou NL: The monoclonal nature of lymphocytes in multiple myeloma. Effects of therapy. Ann Intern Med 83:42–45, 1975Google Scholar
  7. 7.
    Broder S, Humphrey R, Durm M, Blackman M, Meade B, Goldman C, Strober W, Waldmann T: Impaired synthesis of polyclonal (non paraprotein) immunoglobulin by circulating lymphocytes from patients with multiple myeloma. Role of suppressor cells. N Engl J Med 293:887–892, 1975Google Scholar
  8. 8.
    MacKenzie MR, Paglieroni T: Multiple myeloma: An immunologic profile. I. Peripheral blood studies. J Immunol 118:1864–1871, 1977Google Scholar
  9. 9.
    King MA, Wells JV: Cell-bound immunoglobulin on peripheral blood mononuclear cells of patients with myeloma. Clin Exp Immunol 45:522–556, 1981Google Scholar
  10. 10.
    Pilarski LM, Mant MJ, Ruether BA, Belch A: Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients. J Clin Invest 74:1301–1306, 1984Google Scholar
  11. 11.
    Pilarski LM, Mant MJ, Ruether B: Pre-B-cells in peripheral blood of multiple myeloma patients. Blood 66:416–422, 1985Google Scholar
  12. 12.
    Métezeau P, Elguindi I, Goldberg ME: Endocytosis of the membrane immunoglobulins of mouse spleen cells: A quantitative study of its rate, amount and sensitivity to physiological physical and cross-linking agents. EMBO J 3:2235–2242, 1984Google Scholar
  13. 13.
    Durie BGM, Salmon SE: Multiple myeloma, macroglobulinaemia and monoclonal gammapathies. In Recent Advances in Haematology, AV Hoffbrand, MC Brain, J Hirsh (eds). New York, Churchill Livingstone, 1977, pp 243–261Google Scholar
  14. 14.
    Bataille R, Grenier J, Sany J: Serum beta2 microglobulin in myeloma: Optimal use for staging prognosis and treatment. Blood 63:468–476, 1984Google Scholar
  15. 15.
    Brochier J, Magaud JP, Cordier G, Millet I, Marti J, Bryon PA: Heterogeneity of human B lymphocytes as revealed by monoclonal antibodies. Ann Immunol 135:283–299, 1984Google Scholar
  16. 16.
    Poncelet P, Carayon P: Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies. J Immunol Meth 85:67–74, 1985Google Scholar
  17. 17.
    Shimizu K, Muyate T, Kunii A: Circulating immunoglobulin-secreting cells in patients with plasma cell dyscrasia. Blood 55:590–94, 1980Google Scholar
  18. 18.
    Pilarski LM, Ruehter B, Mant MJ: Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels. J Clin Invest 75:2024–2029, 1985Google Scholar
  19. 19.
    Cohen HJ, Gilbersten BB: Human lymphocyte surface immunoglobulin capping. Normal characteristics and anomalous behavior of chronic lymphocytic leukemia lymphocytes. J Immunol 55:84–93, 1975Google Scholar
  20. 20.
    Zucker-Franklin D, Liebes LF, Silber R: Differences in the behavior of the membrane and membrane-associated filamentous structures in normal and chronic lymphocytic leukemia (CLL) lymphocytes. J Immunol 122:97–107, 1979Google Scholar
  21. 21.
    Cooper MD: Pre-B-cells: Normal and abnormal development. J Clin Immunol 1:81–89, 1981Google Scholar
  22. 22.
    Kubagawa H, Vogler LB, Capra JD, Conrad ME, Lawton AR, Cooper MD: Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med 150:792–807, 1979Google Scholar
  23. 23.
    Boccadoro M, Gavarotti P, Fossati G, Massaia M, Pileri A, Durie BGM: Kinetics of circulating B lymphocytes in human myeloma. Blood 61:812–814, 1983Google Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • Xue-Guang Zhang
    • 1
    • 2
  • Bernard Klein
    • 1
  • Christophe Duperray
    • 1
  • Jean Brochier
    • 1
  • Regis Bataille
    • 1
    • 3
  1. 1.INSERM U291MontpellierFrance
  2. 2.Department of PathophysiologySuzhou Medical CollegeSuzhouChina
  3. 3.Service d'Immunorhumatologie, Centre Gui-de-ChauliacHôpital Saint-EloiMontpellier CedexFrance

Personalised recommendations